ArticleFrontiers in cardiovascular medicine2025
A metabolomics study reveals potential plasma biomarkers for predicting post-infarction left ventricular remodeling: findings from the metabolights database.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Left ventricular remodeling (LVR) after ST-segment elevation myocardial infarction (STEMI) is a major determinant of adverse prognosis, yet reliable early biomarkers remain limited. Methods: This secondary analysis of publicly available metabolomic data from the MetaboLights database aimed to explore metabolic signatures associated with left ventricular remodeling (LVR) following STEMI patients. Key differential metabolites were identified through an integrated approach combining multivariate screening (PLS-DA with VIP >1.0) and univariate validation (Log2FC, FDR, Cohen's d). The robustness of principal findings was further verified by bootstrap resampling. These metabolites subsequently underwent comprehensive evaluation through univariate testing, ROC analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Results: Exploratory analysis revealed distinct differences in plasma metabolic profiles between patients with and without LVR. Notably, levels of threonine, glycine, and histidine were observed to be lower in the LVR group, with their respective AUCs of 0.785, 0.748, and 0.745 suggesting potential predictive value. Pathway analysis suggested an enrichment of these metabolites in processes such as amino acid metabolism and energy regulation, which might be linked to disruptions in oxidative stress, inflammatory, and fibrotic pathways. Conclusions: In summary, our preliminary findings suggest that threonine, glycine, and histidine may merit further investigation as potential biomarkers for post-STEMI LVR, and their association with key pathophysiological pathways hints at possible mechanistic roles. Given the absence of clinical and demographic data, combined with the small and imbalanced sample (6 LVR vs. 55 Non-LVR patients), our findings should be interpreted as exploratory and hypothesis-generating. Their clinical predictive utility requires validation in larger, independent prospective cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.